gastroesophageal cancer
The firm has ongoing trials evaluating evorpacept with monoclonal antibodies, checkpoint inhibitors, and antibody-drug conjugates.
UK's MHRA Approves Astellas' Vyloy for CLDN18.2-Positive Gastric Cancer
The approval is based on two trials in which Vyloy plus chemo bested chemo and placebo in advanced CLDN18.2-positive, HER2-negative gastric cancer.
Enhertu Approved in China for HER2-Positive Gastric, Gastroesophageal Junction Cancer
The approval was based on two Phase II trials conducted in Asia that demonstrated response rates of 29 percent and 41 percent, respectively, on Enhertu.
The firm is looking for funding and partnerships to continue demonstrating the capabilities of its mechanistic approach that simulates treatment responses in in silico tumor models.
Natera Signatera MRD Test to Guide, Assess Treatment in Phase II Gastroesophageal Cancer Study
The Signatera ctDNA test will be used to evaluate the efficacy of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in the Phase II DECIPHER trial.